We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




No Benefit for Heparin in the Acute Setting

By HospiMedica International staff writers
Posted on 12 Jan 2012
The use of low-molecular-weight heparin along with graduated compression stockings failed to reduce 30-day all-cause mortality among acutely ill medical patients, according to a new study.

Researchers at University College London (UCL; United Kingdom) and other institutions conducted a placebo-controlled, randomized trial to assess the effect of subcutaneous enoxaparin (40 mg daily) as compared with placebo--both administered to 8,307 patients who were wearing elastic stockings with graduated compression--on the rate of death from any cause at 30 days among hospitalized, acutely ill patients at participating sites in China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia. More...
Inclusion criteria were age of at least 40 years, hospitalization for acute decompensated heart failure (HF), and severe systemic infection with at least one risk factor for venous thromboembolism, or active cancer.

The results showed that the rate of death from any cause at day 30 was 4.9% in the enoxaparin group, as compared with 4.8% in the placebo group; two-week all-cause mortality was similar in the two groups, at 2.9% in each, and three-month all-cause mortality was also similar, with a hazard rate of 8.4% for patients receiving thromboprophylaxis and 8.6% for those receiving placebo. The rate of major bleeding was 0.4% in the enoxaparin group and 0.3% in the placebo group. Analysis revealed that pulmonary failure was the most common cause of death at 30 days; other causes included active cancer, impaired kidney function, two or more coexisting acute illnesses, and chronic pulmonary disease. The study was published in the December 29, 2011, issue of the New England Journal of Medicine (NEJM).

“While thromboprophylaxis in surgical patients has been shown to decrease the rate of lethal pulmonary embolism, acutely ill medical patients may be at risk for death from many causes other than pulmonary embolism, thus diminishing the ability of pharmacologic prophylaxis to improve the overall clinical outcome,” concluded lead author Ajay Kakkar, MBBS, PhD, of UCL, and colleagues. “Another possible reason for the lack of a benefit could be that rates of pulmonary embolism have been reported to be lower in Asia than in Western countries.”

Heparin is a highly sulfated glycosaminoglycan, widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Although it is used principally in medicine for anticoagulation, its true physiological role in the body remains unclear, because blood anticoagulation is achieved mostly by heparan sulfate proteoglycans. It has been proposed that, rather than anticoagulation, the main purpose of heparin is defense at such sites against invading bacteria and other foreign materials.

Related Links:
University College London



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.